Hematopoietic stem cell transplantation for patients with Wiskott-Aldrich syndrome

Wiskott-Aldrich syndrome (WAS) is an X linked congenital disease that presents as eczema, thrombocytopenia and immune deficiency. The only curative procedure for this illness is hematopoietic stem cell transplant (HSCT), preferably from a healthy HLA identical sibling donor. Cord blood is becoming a...

Full description

Saved in:
Bibliographic Details
Published inRevista medíca de Chile Vol. 135; no. 7; pp. 917 - 923
Main Authors Wietstruck P, María Angélica, Zúñiga C, Pamela, Talesnik G, Eduardo, Méndez R, Cecilia, Barriga C, Francisco
Format Journal Article
LanguageSpanish
Published Chile 01.07.2007
Subjects
Child
Child, Preschool
Cord Blood Stem Cell Transplantation - adverse effects
Fatal Outcome
Graft vs Host Disease - etiology
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Infant
Male
Thrombocytopenia - etiology
Transplantation Conditioning
Treatment Outcome
Wiskott-Aldrich Syndrome - surgery
Online AccessGet full text

Cover

More Information
Summary:Wiskott-Aldrich syndrome (WAS) is an X linked congenital disease that presents as eczema, thrombocytopenia and immune deficiency. The only curative procedure for this illness is hematopoietic stem cell transplant (HSCT), preferably from a healthy HLA identical sibling donor. Cord blood is becoming an excellent alternative as stem cell source from unrelated donors. To report our experience with HSCT in children with WAS. Six boys with WAS diagnosed at 1 to 6 months of age were transplanted at our institution. All of them developed eczema and thrombocytopenia. Two had episodes of severe bleeding and three had repetitive infections (two with recurrent pulmonary infections and one a recurrent otitis). Three patients had a positive family history. Two received HSCT from sibling donors and four from unrelated cord blood donors at 7 months to 4 years of age. AH 6 patients had full hematopoietic engraftment after transplantation. Three had mild chronic graft-versus- host disease which responded to immune suppressive therapy. One patient died of cytomegalovirus related pneumonia 111 days after grafting. The other 5 patients are alive and healthy 11 to 104 months after transplantation. HSCT is an effective treatment for patients with WAS. The procedure should be done as soon as diagnosis is confirmed and before life threatening infections occur.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Report-3
ObjectType-Case Study-4
ISSN:0034-9887
0717-6163